Search research articles
Contact Us
Filters
Showing results (461-470 of 512) with videos related to
Page
of 52
Sort By:
Molecular Cancer
|
October 4, 2024
Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development
Damien Vasseur, Ludovic Bigot, Kristi Beshiri, et al.
Lancet (London, England)
|
January 19, 2016
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
Fabrice Barlesi, Julien Mazieres, Jean-Philippe Merlio, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 16, 2020
The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study
Jean-Marie Michot, Ariane Lappara, Jérôme Le Pavec, et al.
The Lancet. Oncology
|
April 1, 2020
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
José Trigo, Vivek Subbiah, Benjamin Besse, et al.
NPJ Precision Oncology
|
September 23, 2020
Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy
Gonzalo Recondo, Linda Mahjoubi, Aline Maillard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 8, 2022
Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Fabrice Barlesi, Pascale Tomasini, Maryam Karimi, et al.
Nature Cancer
|
February 4, 2022
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression
Lucile Vanhersecke, Maxime Brunet, Jean-Philippe Guégan, et al.
JCO Precision Oncology
|
March 2, 2023
Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors
Mihaela Aldea, Marco Tagliamento, Arnaud Bayle, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
December 7, 2023
Immune checkpoints are predominantly co-expressed by clonally expanded CD4<sup>+</sup>FoxP3<sup>+</sup> intratumoral T-cells in primary human cancers
Delphine Bredel, Edi Tihic, Séverine Mouraud, et al.
The New England Journal of Medicine
|
January 10, 2024
Repotrectinib in <i>ROS1</i> Fusion-Positive Non-Small-Cell Lung Cancer
Alexander Drilon, D Ross Camidge, Jessica J Lin, et al.
Page
of 52
Search research articles
Search
Showing results (461-470 of 512) with videos related to
Sort By:
Page
of 52
Molecular Cancer
|
October 4, 2024
Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development
Damien Vasseur, Ludovic Bigot, Kristi Beshiri, et al.
Lancet (London, England)
|
January 19, 2016
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
Fabrice Barlesi, Julien Mazieres, Jean-Philippe Merlio, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 16, 2020
The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study
Jean-Marie Michot, Ariane Lappara, Jérôme Le Pavec, et al.
The Lancet. Oncology
|
April 1, 2020
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
José Trigo, Vivek Subbiah, Benjamin Besse, et al.
NPJ Precision Oncology
|
September 23, 2020
Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy
Gonzalo Recondo, Linda Mahjoubi, Aline Maillard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 8, 2022
Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Fabrice Barlesi, Pascale Tomasini, Maryam Karimi, et al.
Nature Cancer
|
February 4, 2022
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression
Lucile Vanhersecke, Maxime Brunet, Jean-Philippe Guégan, et al.
JCO Precision Oncology
|
March 2, 2023
Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors
Mihaela Aldea, Marco Tagliamento, Arnaud Bayle, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
December 7, 2023
Immune checkpoints are predominantly co-expressed by clonally expanded CD4<sup>+</sup>FoxP3<sup>+</sup> intratumoral T-cells in primary human cancers
Delphine Bredel, Edi Tihic, Séverine Mouraud, et al.
The New England Journal of Medicine
|
January 10, 2024
Repotrectinib in <i>ROS1</i> Fusion-Positive Non-Small-Cell Lung Cancer
Alexander Drilon, D Ross Camidge, Jessica J Lin, et al.
Page
of 52